{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T05:19:08Z","timestamp":1732943948866,"version":"3.30.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,29]]},"DOI":"10.7759\/cureus.74750","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T15:23:11Z","timestamp":1732893791000},"source":"Crossref","is-referenced-by-count":0,"title":["Anticoagulation Reversal in Intracerebral Hemorrhage: A Case Report on the Efficacy of Andexanet Alfa in an Apixaban-Treated Patient"],"prefix":"10.7759","author":[{"given":"Corina","family":"Roman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romeo","family":"Mihaila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosmin Nicodim","family":"Cindea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Iliescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iulian","family":"Roman-Filip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca Rafila","family":"Stingaciu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Breazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicentiu","family":"Saceleanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04043-8","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis","volume":"26","author":"Costa OS","year":"2022","unstructured":"Costa OS, Connolly SJ, Sharma M, Beyer-Westendorf J, Christoph MJ, Lovelace B, Coleman CI. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Crit Care. 2022, 26:180. 10.1186\/s13054-022-04043-8","journal-title":"Crit Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.32.4.891","article-title":"The ICH score: a simple, reliable grading scale for intracerebral hemorrhage","volume":"32","author":"Hemphill JC 3rd","year":"2001","unstructured":"Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001, 32:891-7. 10.1161\/01.str.32.4.891","journal-title":"Stroke"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu JB","year":"2015","unstructured":"Kuramatsu JB, Gerner ST, Schellinger PD, et al.. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015, 313:824-36. 10.1001\/jama.2015.0846","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-820746","article-title":"Treatment of bleeding complications in patients on anticoagulant therapy","volume":"133","author":"Piran S","year":"2019","unstructured":"Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019, 133:425-35. 10.1182\/blood-2018-06-820746","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S51006","article-title":"Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence","volume":"8","author":"Zalpour A","year":"2014","unstructured":"Zalpour A, Oo TH. Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Drug Des Devel Ther. 2014, 8:2181-91. 10.2147\/DDDT.S51006","journal-title":"Drug Des Devel Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123399","article-title":"Andexanet alfa for reversal of factor Xa inhibitors in intracranial hemorrhage: observational cohort study","volume":"11","author":"Rauch S","year":"2022","unstructured":"Rauch S, M\u00fcller HP, Dreyhaupt J, Ludolph AC, Kassubek J, Althaus K. Andexanet alfa for reversal of factor Xa inhibitors in intracranial hemorrhage: observational cohort study. J Clin Med. 2022, 11:3399. 10.3390\/jcm11123399","journal-title":"J Clin Med"},{"key":"ref7","article-title":"Implications for language acquisition theories: a fresh look at the \u201cgenie case\u201d.","volume":"12","author":"G\u00ee\u021b\u0103","unstructured":"G\u00ee\u021b\u0103, IE. Implications for language acquisition theories: a fresh look at the \u201cgenie case\u201d.. Revista Transilvania. 12:57-60.","journal-title":"Revista Transilvania"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.30687\/AnnOr\/2385-3042\/2022\/01\/023","article-title":"Chinese literature in Romania in the context of Sino-Romanian economic and political relations (1950-2018)","volume":"58","author":"Cindea IE","year":"2022","unstructured":"Cindea IE, Wang J. Chinese literature in Romania in the context of Sino-Romanian economic and political relations (1950-2018). Annali di Ca\u2019 Foscari. 2022, 58:689-708. 10.30687\/AnnOr\/2385-3042\/2022\/01\/023","journal-title":"Annali di Ca\u2019 Foscari"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.24818\/SIC\/2021\/04.01","article-title":"An in-depth study of Chinese culturemes - carriers of the most subtle cultural allusions - excerpted from Chinese contemporary novels in Romanian translation","author":"G\u00ee\u021b\u0103 IEC","year":"2022","unstructured":"G\u00ee\u021b\u0103 IEC. An in-depth study of Chinese culturemes - carriers of the most subtle cultural allusions - excerpted from Chinese contemporary novels in Romanian translation. Syn Comm. 2022, 1-12. 10.24818\/SIC\/2021\/04.01","journal-title":"Syn Comm"},{"key":"ref10","article-title":"Thrombosis generation abnormalities in spontaneous intracerebral haemorrhage","volume":"33","author":"Cindea CN","year":"2019","unstructured":"Cindea CN, Mih\u0103il\u0103 RG, S\u0103celeanu VM. Thrombosis generation abnormalities in spontaneous intracerebral haemorrhage. Romanian Neurosurgery. 2019, 33:54.","journal-title":"Romanian Neurosurgery"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11121604","article-title":"Intraoperative rupture of an intracranial, extradural hydatid cyst: case report and treatment options","volume":"11","author":"Cindea CN","year":"2021","unstructured":"Cindea CN, Saceleanu V, Saceleanu A. Intraoperative rupture of an intracranial, extradural hydatid cyst: case report and treatment options. Brain Sci. 2021, 11:1604. 10.3390\/brainsci11121604","journal-title":"Brain Sci"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Andexanet alfa. (2024). Accessed. March 2024: https:\/\/www.cda-amc.ca\/andexanet-alfa.","DOI":"10.1007\/s40278-024-66024-2"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s15006-020-0709-z","article-title":"Ondexxya\u00ae\u2014 faktor-XA-Hemmer-antidot: management Schwerer Blutungen","volume":"162","author":"Wedekind S","year":"2020","unstructured":"Wedekind S. Ondexxya\u00ae\u2014 faktor-XA-Hemmer-antidot: management Schwerer Blutungen. MMW Fortschr Med. 2020, 162:73. 10.1007\/s15006-020-0709-z","journal-title":"MMW Fortschr Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly SJ","year":"2019","unstructured":"Connolly SJ, Crowther M, Eikelboom JW, et al.. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019, 380:1326-35. 10.1056\/NEJMoa1814051","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2042106","article-title":"Cost-effectiveness of andexanet\u00a0alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US","volume":"25","author":"Fanikos J","year":"2022","unstructured":"Fanikos J, Goldstein JN, Lovelace B, Beaubrun AC, Blissett RS, Arag\u00e3o F. Cost-effectiveness of andexanet\u00a0alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US. J Med Econ. 2022, 25:309-20. 10.1080\/13696998.2022.2042106","journal-title":"J Med Econ"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"CADTH reimbursement review - andexanet alfa (Ondexxya) - sponsor. AstraZeneca Canada Inc.. (2023). Accessed: December 2023: https:\/\/canadacommons.ca\/artifacts\/11462206\/cadth-reimbursement-review-andexanet-alfa-ondexxya-sponsor\/12353271\/.","DOI":"10.51731\/cjht.2023.806"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/322876-anticoagulation-reversal-in-intracerebral-hemorrhage-a-case-report-on-the-efficacy-of-andexanet-alfa-in-an-apixaban-treated-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T15:23:14Z","timestamp":1732893794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/322876-anticoagulation-reversal-in-intracerebral-hemorrhage-a-case-report-on-the-efficacy-of-andexanet-alfa-in-an-apixaban-treated-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.74750","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}